Outcomes Associated with a Pediatric Intensive Care Unit Sedation Weaning Protocol

Abstract

Objective This article compares patient outcomes before and after implementation of a risk stratified pediatric sedation weaning protocol.

Methods This observational cohort study, in a 30-bed tertiary care pediatric intensive care unit (PICU), included patients requiring opioid, benzodiazepine, and/or dexmedetomidine infusions. Outcomes (duration of wean, PICU length of stay [LOS], and Withdrawal Assessment Tool [WAT-1] scores) were collected by retrospective chart review for 12 months before and after protocol implementation. The influence of the protocol was assessed using an interrupted time series (ITS) analysis.

Results There were 49 patients before and 47 patients after protocol implementation. Median opioid wean duration preprotocol was 10.5 days (interquartile range [IQR]: 4.25, 20.75) versus 9.0 days (IQR: 5.0, 16.75) postprotocol (p = 0.66). Median benzodiazepine wean duration was 11.5 days (IQR: 3.0, 19.8) preprotocol versus 5.0 days (IQR: 2.0, 13.5) postprotocol (p = 0.31). Median alpha-agonist wean duration was 7.0 days (IQR: 3.5, 17.0) preprotocol versus 3 days (IQR: 1.0, 14.0) postprotocol (p = 0.03). The ITS indicated a reduction in opioid wean by 6.7 days (p = 0.35), a reduction in benzodiazepine wean by 13.4 days (p = 0.12), and a reduction in alpha-agonist wean by 12.9 days (p = 0.06). WAT-1 scores > 3 (12.6% preprotocol vs. 9.9% postprotocol, p = 0.569) and PICU LOS (16.0 days [IQR: 11.0, 26.0] vs. 17.0 days [IQR: 11.0, 26.5], p = 0.796) did not differ between groups.

Conclusion Implementation of a risk stratified sedation weaning protocol in the PICU was associated with a significant reduction in alpha-agonist wean duration without a significant increase in withdrawal symptoms.

Keywords

sedation - weaning - withdrawal - opioids - dexmedetomidine

^* Work performed at Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee

Publikationsverlauf

Eingereicht: 24. Februar 2023

Angenommen: 17. April 2023

Artikel online veröffentlicht:
26. Mai 2023

• References

• 1 Sanchez-Pinto LN, Nelson LP, Lieu P. et al. Implementation of a risk-stratified opioid weaning protocol in a pediatric intensive care unit. J Crit Care 2018; 43: 214-219
• 2 Amirnovin R, Sanchez-Pinto LN, Okuhara C. et al. Implementation of a risk-stratified opioid and benzodiazepine weaning protocol in a pediatric cardiac ICU. Pediatr Crit Care Med 2018; 19 (11) 1024-1032
• 3 Abdouni R, Reyburn-Orne T, Youssef TH, Haddad IY, Gerkin RD. Impact of a standardized treatment guideline for pediatric iatrogenic opioid dependence: a quality improvement initiative. J Pediatr Pharmacol Ther 2016; 21 (01) 54-65
• 4 Vipond JM, Heiberger AL, Thompson PA, Huber JN. Shortened taper duration after implementation of a standardized protocol for iatrogenic benzodiazepine and opioid withdrawal in pediatric patients: results of a cohort study. Pediatr Qual Saf 2018; 3 (03) e079
• 5 Fenn III NE, Plake KS. Opioid and benzodiazepine weaning in pediatric patients: review of current literature. Pharmacotherapy 2017; 37 (11) 1458-1468
• 6 Bowens CD, Thompson JA, Thompson MT, Breitzka RL, Thompson DG, Sheeran PW. A trial of methadone tapering schedules in pediatric intensive care unit patients exposed to prolonged sedative infusions. Pediatr Crit Care Med 2011; 12 (05) 504-511
• 7 Robertson RC, Darsey E, Fortenberry JD, Pettignano R, Hartley G. Evaluation of an opiate-weaning protocol using methadone in pediatric intensive care unit patients. Pediatr Crit Care Med 2000; 1 (02) 119-123
• 8 Berens RJ, Meyer MT, Mikhailov TA. et al. A prospective evaluation of opioid weaning in opioid-dependent pediatric critical care patients. Anesth Analg 2006; 102 (04) 1045-1050
• 9 Meyer MM, Berens RJ. Efficacy of an enteral 10-day methadone wean to prevent opioid withdrawal in fentanyl-tolerant pediatric intensive care unit patients. Pediatr Crit Care Med 2001; 2 (04) 329-333
• 10 Walters RA, Izquierdo M, Rodriguez JC, Stevens JS, Lavandosky G. Iatrogenic opiate withdrawal in pediatric patients: implementation of a standardized methadone weaning protocol and withdrawal assessment tool. J Pharm Pract 2021; 34 (03) 417-422
• 11 D'Souza G, Wren AA, Almgren C, Ross AC, Marshall A, Golianu B. Pharmacological strategies for decreasing opioid therapy and management of side effects from chronic use. Children (Basel) 2018; 5 (12) 163
• 12 Anand KJ, Willson DF, Berger J. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network. Tolerance and withdrawal from prolonged opioid use in critically ill children. Pediatrics 2010; 125 (05) e1208-e1225
• 13 Curley MAQ, Wypij D, Watson RS. et al; RESTORE Study Investigators and the Pediatric Acute Lung Injury and Sepsis Investigators Network. Protocolized sedation vs usual care in pediatric patients mechanically ventilated for acute respiratory failure: a randomized clinical trial. JAMA 2015; 313 (04) 379-389
• 14 Minhas MA, Velasquez AG, Kaul A, Salinas PD, Celi LA. Effect of protocolized sedation on clinical outcomes in mechanically ventilated intensive care unit patients: a systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2015; 90 (05) 613-623
• 15 Smith HAB, Besunder JB, Betters KA. et al. 2022 Society of Critical Care Medicine clinical practice guidelines on prevention and management of pain, agitation, neuromuscular blockade, and delirium in critically ill pediatric patients with consideration of the ICU environment and early mobility. Pediatr Crit Care Med 2022; 23 (02) e74-e110
• 16 Grant MJC, Schneider JB, Asaro LA. et al; Randomized Evaluation of Sedation Titration for Respiratory Failure Study Investigators. Dexmedetomidine use in critically ill children with acute respiratory failure. Pediatr Crit Care Med 2016; 17 (12) 1131-1141
• 17 Czaja AS, Zimmerman JJ. The use of dexmedetomidine in critically ill children. Pediatr Crit Care Med 2009; 10 (03) 381-386
• 18 Thompson RZ, Gardner BM, Autry EB, Day SB, Krishna AS. Survey of the current use of dexmedetomidine and management of withdrawal symptoms in critically ill children. J Pediatr Pharmacol Ther 2019; 24 (01) 16-21
• 19 Pandharipande PP, Pun BT, Herr DL. et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA 2007; 298 (22) 2644-2653
• 20 Manning AN, Bezzo LK, Hobson JK, Zoeller JE, Brown CA, Henderson KJ. Dexmedetomidine dosing to prevent pediatric emergence delirium. AANA J 2020; 88 (05) 359-364
• 21 Bouajram RH, Bhatt K, Croci R. et al. Incidence of dexmedetomidine withdrawal in adult critically ill patients: a pilot study. Crit Care Explor 2019; 1 (08) e0035
• 22 Whalen LD, Di Gennaro JL, Irby GA, Yanay O, Zimmerman JJ. Long-term dexmedetomidine use and safety profile among critically ill children and neonates. Pediatr Crit Care Med 2014; 15 (08) 706-714
• 23 Haenecour AS, Seto W, Urbain CM, Stephens D, Laussen PC, Balit CR. Prolonged dexmedetomidine infusion and drug withdrawal in critically ill children. J Pediatr Pharmacol Ther 2017; 22 (06) 453-460
• 24 Franck LS, Scoppettuolo LA, Wypij D, Curley MAQ. Validity and generalizability of the Withdrawal Assessment Tool-1 (WAT-1) for monitoring iatrogenic withdrawal syndrome in pediatric patients. Pain 2012; 153 (01) 142-148